662 related articles for article (PubMed ID: 24269664)
1. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.
Brown JW; Rueter LE; Zhang M
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():53-62. PubMed ID: 24269664
[TBL] [Abstract][Full Text] [Related]
2. Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia.
Karamihalev S; Prickaerts J; van Goethem NP
Behav Brain Res; 2014 Oct; 272():248-51. PubMed ID: 25036424
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia.
Brown JW; Whitehead CA; Basso AM; Rueter LE; Zhang M
Int J Neuropsychopharmacol; 2013 May; 16(4):889-904. PubMed ID: 22906530
[TBL] [Abstract][Full Text] [Related]
4. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
Ishiyama T; Tokuda K; Ishibashi T; Ito A; Toma S; Ohno Y
Eur J Pharmacol; 2007 Oct; 572(2-3):160-70. PubMed ID: 17662268
[TBL] [Abstract][Full Text] [Related]
5. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.
Gacsályi I; Nagy K; Pallagi K; Lévay G; Hársing LG; Móricz K; Kertész S; Varga P; Haller J; Gigler G; Szénási G; Barkóczy J; Bíró J; Spedding M; Antoni FA
Neuropharmacology; 2013 Jan; 64():254-63. PubMed ID: 22824189
[TBL] [Abstract][Full Text] [Related]
6. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.
Karasawa J; Hashimoto K; Chaki S
Behav Brain Res; 2008 Jan; 186(1):78-83. PubMed ID: 17854919
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic drugs reverse MK-801-induced cognitive and social interaction deficits in zebrafish (Danio rerio).
Seibt KJ; Piato AL; da Luz Oliveira R; Capiotti KM; Vianna MR; Bonan CD
Behav Brain Res; 2011 Oct; 224(1):135-9. PubMed ID: 21669233
[TBL] [Abstract][Full Text] [Related]
8. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm.
Abdul-Monim Z; Reynolds GP; Neill JC
Behav Brain Res; 2006 May; 169(2):263-73. PubMed ID: 16500717
[TBL] [Abstract][Full Text] [Related]
9. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
[TBL] [Abstract][Full Text] [Related]
10. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia.
Rajagopal L; Massey BW; Huang M; Oyamada Y; Meltzer HY
Curr Pharm Des; 2014; 20(31):5104-14. PubMed ID: 24345269
[TBL] [Abstract][Full Text] [Related]
11. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.
Gaisler-Salomon I; Weiner I
Psychopharmacology (Berl); 2003 Apr; 166(4):333-42. PubMed ID: 12599023
[TBL] [Abstract][Full Text] [Related]
12. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone.
Horisawa T; Ishibashi T; Nishikawa H; Enomoto T; Toma S; Ishiyama T; Taiji M
Behav Brain Res; 2011 Jun; 220(1):83-90. PubMed ID: 21277905
[TBL] [Abstract][Full Text] [Related]
13. Effects of risperidone, clozapine and the 5-HT6 antagonist GSK-742457 on PCP-induced deficits in reversal learning in the two-lever operant task in male Sprague Dawley rats.
de Bruin NM; van Drimmelen M; Kops M; van Elk J; Wetering MM; Schwienbacher I
Behav Brain Res; 2013 May; 244():15-28. PubMed ID: 23384714
[TBL] [Abstract][Full Text] [Related]
14. Effects of the cognition impairer MK-801 on learning and memory in mice and rats.
van der Staay FJ; Rutten K; Erb C; Blokland A
Behav Brain Res; 2011 Jun; 220(1):215-29. PubMed ID: 21310186
[TBL] [Abstract][Full Text] [Related]
15. Clozapine and glycinamide prevent MK-801-induced deficits in the novel object recognition (NOR) test in the domestic rabbit (Oryctolagus cuniculus).
Hoffman KL; Basurto E
Behav Brain Res; 2014 Sep; 271():203-11. PubMed ID: 24933188
[TBL] [Abstract][Full Text] [Related]
16. MK-801 and amphetamine result in dissociable profiles of cognitive impairment in a rodent paired associates learning task with relevance for schizophrenia.
Talpos J; Aerts N; Waddell J; Steckler T
Psychopharmacology (Berl); 2015 Nov; 232(21-22):3911-20. PubMed ID: 25902874
[TBL] [Abstract][Full Text] [Related]
17. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia.
Mastropaolo J; Rosse RB; Deutsch SI
Behav Brain Res; 2004 Aug; 153(2):419-22. PubMed ID: 15265637
[TBL] [Abstract][Full Text] [Related]
18. 3α5β-Pregnanolone glutamate, a use-dependent NMDA antagonist, reversed spatial learning deficit in an animal model of schizophrenia.
Vales K; Rambousek L; Holubova K; Svoboda J; Bubenikova-Valesova V; Chodounska H; Vyklicky L; Stuchlik A
Behav Brain Res; 2012 Nov; 235(1):82-8. PubMed ID: 22820236
[TBL] [Abstract][Full Text] [Related]
19. Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.
Zhang C; Fang Y; Xu L
Schizophr Res; 2014 Nov; 159(2-3):376-84. PubMed ID: 25219486
[TBL] [Abstract][Full Text] [Related]
20. ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia.
Yamazaki M; Harada K; Yamamoto N; Yarimizu J; Okabe M; Shimada T; Ni K; Matsuoka N
Eur Neuropsychopharmacol; 2014 Oct; 24(10):1698-708. PubMed ID: 25108314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
